Newswire (Published: Tuesday, October 10, 2017, Received: Thursday, October 5, 2017, 7:00:12 PM CDT)

Word Count: 579

New Prostate Cancer Study Findings Have Been Reported by E. Roggero and Colleagues (The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression)

By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Oncology - Prostate Cancer. According to news reporting originating in Bellinzona, Switzerland, by NewsRx journalists, research stated, "Five-year survival in patients with localized prostate cancer (PCa) is nearly 100%, but metastatic disease still remains incurable. Clinical management of metastatic patients has become increasingly complex as novel therapeutic strategies have emerged."

The news reporters obtained a quote from the research, "This study aims at evaluating the impact of the first metastatic progression on the outcome of PCa patients treated with curative intent. The analysis was conducted using data of 913 cases of localized PCa diagnosed between 2000 and 2014. All patients were treated with curative surgery (N = 382) or radiotherapy (N = 531) with or without adjuvant therapy. All metastases were radiologically documented. The prognostic impact of the first site of metastasis on metastasis-free survival (MFS) and PCa-specific survival (PCaSS) was investigated by univariate and multivariate analyses. One hundred and thirty-six (14.9%) patients developed a metastatic hormone-sensitive PCa and had a median PCaSS of 50.4 months after first metastatic progression. Bone (N = 50, 36.8%) and LN or locoregional (N = 52, 38.2%) metastases occurred more frequently with a median PCaSS of 39.7 and 137 months respectively (p < 0.0001). Seven patients developed visceral metastasis only (5.1%; liver, lung, brain) and 27 (19.9%) concurrent metastases; this last group was associated with the worst survival with a median value of only 17 months. Thus, each subgroup exhibited a survival after metastasis significantly different from each other. In multivariate analysis the site of the first metastasis was an independent prognostic factor for PCaSS along with Gleason score at diagnosis. The correlation between survival and first site of metastasis was confirmed separately for each therapy subgroup. Median metastasis-free survival from primary diagnosis to first metastasis was not correlated with the first site of metastasis. In non-metastatic PCa patients treated with curative intent, the PCa-specific survival time depends on the time after metastatic progression rather than the time from diagnosis to metastasis. Moreover, the site of first metastasis is an independent prognostic factor for PCaSS."

According to the news reporters, the research concluded: "Our data confirm that the first metastatic event may confer a differential prognostic impact and may help in identifying patient at high risk of death supporting the treatmentdecision making process following metastatic progression."

For more information on this research see: The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression. BMC Cancer, 2017;17():1-8. BMC Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; BMC Cancer - www.biomedcentral.com/bmccancer/)

Our news correspondents report that additional information may be obtained by contacting E. Roggero, Oncol Inst Southern Switzerland IOSI, Medical Oncol Unit, CH-6500 Bellinzona, Switzerland. Additional authors for this research include C.N. Azinwi, B. Marongiu, G. Pesce, F. Stoffel and M. Pascale (see also Oncology - Prostate Cancer).

Keywords for this news article include: Bellinzona, Switzerland, Europe, Cancer, Risk and Prevention, Prostatic Neoplasms, Prostate Cancer, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Biomed Central Limited

Places

Northern Europe
Western Europe
Switzerland
United Kingdom
Europe
England
London

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
                  Clinical Outcomes